Beta Drugs Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 18.8%)
- Efficient capital deployment (ROCE 19.2%)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
BETA · as of Dec 2025
| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Promoters | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% |
| FII | 0.32% | 0.32% | 0.32% | 0.90% | 1.16% | 1.15% |
| DII | 0.02% | 0.02% | 0.06% | 0.12% | 0.16% | 0.17% |
| Public | 32.93% | 32.92% | 32.87% | 32.25% | 31.95% | 31.95% |
Latest News
All newsBeta Drugs reports Q2FY26 financial results.
*Beta Drugs reports Q2FY26 financial results.* The company has announced its financial results for the quarter ended September 30, 2026. Results were in line with market expectations, with no major deviations in revenue or profit. **No guidance update or significant corporate actions were disclosed.** 📊 *STOCKS:* BETADRUG | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Beta Drugs publishes mandatory notice in newspaper
Beta Drugs Limited has published a copy of its newspaper notice as part of regulatory requirements. This is a routine corporate filing submitted to the NSE. No financial or operational updates were disclosed. Such filings are standard and do not impact trading fundamentals. 📊 *STOCKS:* BETADRX | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Beta Drugs hosts analyst and investor meet
*Beta Drugs hosts analyst and investor meet* to discuss business updates and strategy. The company provided insights on operations and future outlook during the call. No **financial figures** or major announcements were highlighted in the filing. The session aimed to enhance investor engagement and transparency. 📊 *STOCKS:* BETADRX | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnalystMeet
Beta Drugs to hold shareholder meeting on Sept 30, 2026
*Beta Drugs to hold shareholder meeting on Sept 30, 2026.* The company has scheduled a meeting of shareholders on **September 30, 2026**, as per an NSE filing. Purpose of the meeting is not disclosed yet. Such meetings often address corporate proposals or governance matters. 📊 *STOCKS:* $BETADRUG | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting
Beta Drugs announces regulatory and commercialisation updates
*Beta Drugs announces regulatory and commercialisation updates.* The company provided a general corporate update regarding its regulatory filings and commercialisation progress. No financial figures or major milestones were disclosed. Impact on trading expected to be minimal. 📊 *STOCKS:* BETADRUG | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
Beta Drugs updates analysts and institutional investors.
*Beta Drugs updates analysts and institutional investors.* The company held a recent investor meet to share updates, as per a corporate filing. Details on financial performance or strategic shifts were not disclosed. Traders may await further clarity from the discussion. 📊 *STOCKS:* $BETADRX | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Beta Drugs publishes mandatory newspaper notice
*Beta Drugs publishes mandatory newspaper notice.* This is a routine compliance filing with the NSE, involving the republication of corporate information in print media. Such notices are standard procedural requirements and do not indicate business changes. No financial or operational impact is expected. 📊 *STOCKS:* $BETA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
About Beta Drugs Limited
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]
HealthcarePharmaceuticals & Biotechnology